BSH 2024 | Addressing cardiotoxicity following CAR-T therapy and improving clinical practice
Arjun Ghosh, MBBS, MSc, PhD, FHEA, FACC, FESC, FRCP, FICOS, University College London Hospitals, London, UK, discusses cardiotoxicity following CAR T-cell therapy, an emerging area of concern for both hematologists and cardiologists as the scope of the indications for this therapeutic option widens. A significant proportion of patients are at risk of developing cardiotoxicity; however, with increasing real-world data, the understanding of how to manage these patients is improving. Dr Ghosh highlights the efficacy of tocilizumab treatment as prophylaxis for both cytokine release syndrome (CRS) and cardiotoxicity following CAR-T. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) Congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
